Sociedad Americana de Hirudoterapia

Decreasing complications of pectoralis major muscle flap reconstruction with two modalities of negative pressure wound therapy

Research article published in Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society (2022)

Última actualización: 1 de noviembre de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de la evidenciaReferencia del artículo
Evidencia: Informe de investigaciónSeguridad y control de infeccionesMyllykangas et al. · Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society, 2022

Resumen

BACKGROUND AND OBJECTIVE: Deep sternal wound infection is a feared complication of open-heart surgery. Negative pressure wound therapy has gained an important role in the treatment of deep sternal wound infection. Incisional negative pressure wound therapy has been introduced as a method to prevent wound complications after sternotomy, and lately, after flap reconstructions in the treatment of deep sternal wound infection. We aimed to study if incisional negative pressure wound therapy with PICO™ had similar beneficial effect described earlier with competing commercial devices. METHODS: This study included 82 patients treated with pectoralis major muscle flap for deep sternal wound infection during the years 2006-2020. PICO group consisted of 24 patients treated with preoperative negative pressure wound therapy and postoperative incisional negative pressure wound therapy (PICO™). Two control groups included 48 patients with conventional treatment and 10 patients with preoperative negative pressure wound therapy only. RESULTS: In the PICO group, the complication rate declined from 50.0% to 33.30%, major complication rate from 29.2% to 12.5%, and need for an additional flap from 14.6.% to 4.2% when compared to conventional treatment. The length of hospital stay decreased as well. Preoperative negative pressure wound therapy alone was associated with moderate decline in the complication rates. In addition, we described the use of split pectoralis major muscle flap reconstruction in 57 patients. To our knowledge, this is the largest published patient series describing this method in the treatment of deep sternal wound infection. CONCLUSIONS: Incisional negative pressure wound therapy with PICO™ seems beneficial after flap reconstruction. Split pectoralis major muscle flap is a versatile reconstruction option suitable to be used as a workhorse in the treatment of deep sternal wound infection.

Resumen tomado de PubMed (NCBI) para el registro citado, en el idioma original. La versión de referencia es la de la publicación original.

El resumen se deja sin traducir para conservar la redacción original de los autores.

Tipo de publicaciónJournal Article
Términos MeSH indexadosHumansNegative-Pressure Wound TherapyPectoralis MusclesRetrospective StudiesSternotomySurgical FlapsSurgical Wound InfectionTreatment Outcome

Síntesis

Peer-reviewed research on infection control, antibiotic prophylaxis, and safety relevant to leech therapy and microsurgical reconstruction. Indexed in PubMed and verified against the NCBI record.

Citación

Referencia (estilo Vancouver)

Myllykangas HM, Halonen J, Husso A, Berg LT. Decreasing complications of pectoralis major muscle flap reconstruction with two modalities of negative pressure wound therapy. Scand J Surg. 2022;111(1):14574969211043330. doi:10.1177/14574969211043330. PMID: 34486448

Los datos bibliográficos (autores, volumen, páginas, DOI) proceden del registro de PubMed.

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Investigación relacionada

Añadido a la biblioteca ASH: 28 de mayo de 2026 · Última actualización del sitio: 1 de noviembre de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.